论文部分内容阅读
生物体内每时每刻都会有各式各样的短暂相互作用发生,它们单独或协同发挥着生物学效应。生物分子间的这些短暂相互作用的重要性已经得到了普遍认可,一种新的药物设计模式也因此被提出,即短暂结合药物设计,这种新设计模式的出现对以寻找最高靶标亲和物为基础的传统药物设计模式提出了质疑和挑战。本文除了对短暂结合药物形成的三种结合方式,包括高离解率结合、多价结合和多靶点结合进行探讨外,还对目前可用于短暂结合作用筛选的一些技术进行了总结。虽然这种新的药物设计模式有巨大的开发潜力,但是一些研究者仍然坚持认为弱结合物没有价值,这给短暂结合药物开发带来了巨大阻力,因此,这种新的设计思想必须让更多的人认同和接受。
Every moment in the body, there is a wide variety of short-lived interactions that act alone or in concert to create biological effects. The importance of these transient interactions between biomolecules has been generally recognized. A new drug design paradigm has therefore been proposed that incorporates short-term drug design and the emergence of this new design paradigm in search of the highest target affinity As the basis for the traditional model of drug design questioned and challenged. In addition to the three combinations of short-term drug binding, including high dissociation rate binding, multivalent binding and multi-target binding, some techniques currently available for short-term binding screening are also summarized. Although this new drug design paradigm has great potential for development, some researchers still insist that the weak conjugate has no value, which has brought great resistance to the short-term drug development, therefore, this new design idea must make more Many people agree and accept.